Single Cell Analysis Market Size to Worth Around USD 18.89 Bn by 2030

According to Nova one advisor, the global Single Cell Analysis market size is expected to be worth around USD 18.89 billion by 2030 from valued at USD 4.97 billion in 2022 and poised to grow at a CAGR of 18.22% from 2022 to 2030.

Get the Free Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/7579

Key Takeaways:

• By product, the consumables segment held the largest revenue share in 2021. The segment is anticipated to be driven by the extensive use of consumables in genetic research, exosome analysis, and RNA and DNA isolation
• Based on application, the cancer segment captured the largest revenue share in 2021. The segment is being driven by single-cell analysis, which has shown to be successful for earlier cancer diagnoses. These techniques make it simple to determine cell kinds, mutation rates, and growth settings
• In terms of workflow, the single cell isolation and library preparation segment held the largest revenue share in 2021. Increasing research using single-cell analysis is anticipated to boost the revenue growth
• Based on end-user, the academic and research laboratories segment held the largest revenue share in 2021. The widespread use of different SEA techniques in research settings has been influenced by a sizeable number of ongoing research projects at academic institutions that use SEA assays
• North America held the largest revenue share in 2021. This is mostly attributed to the occurrence of significant market participants and rising R&D spending and federal assistance
• Asia Pacific is expected to grow at the highest rate over the forecast period owing to factors such as the increasing prevalence of target diseases, growing aging population, and rising single cell technology adoption

Report Scope of the Single Cell Analysis Market

Immediate Delivery Available | Buy this Premium Research Report@ https://www.novaoneadvisor.com/report/checkout/7579

Technology advances, expanding applications in cancer research, and higher government funding for cell-based research are the main drivers of the market. In addition, the market is advancing as a result of the COVID-19 pandemic. For instance, in January 2021, according to the American Journal of Physiology, variations in the peripheral blood mononuclear cellular profiles of COVID-19-infected patients were examined by using single-cell analysis (SEA) through mass cytometry, which supplemented the industry growth.

Government agencies around the world have increased funding for vaccine development and production in response to the ongoing pandemic’s economic and social costs, which has increased the use of SEA tools for COVID-19 research. In order to develop better prognostic and diagnostic indicators and establish suitable therapeutic approaches for people with serious disease presentation, it is essential to know the host immune response throughout pathogenicity. Therefore, the market is positively impacted by COVID-19 because single-cell analysis helps in the assessment of peripheral immune function in the disease and makes new contributions to the study of the disease’s pathophysiology and treatment possibilities.

Single-cell technology aids in the molecular level examination of pathways and processes as well as the assessment of cellular heterogeneity. This technology is developing rapidly with uses in oncology, immunology, and other fields. Further, the development of sophisticated tools that make transcriptomic and proteomic processes simpler is boosting the use of SEA methods. Researchers are now able to comprehensively examine previously unstudied uncommon cell types owing to developments in scRNA sequencing (scRNAseq). The application of single-cell genomic/transcriptomic analysis in the biomedical area has been greatly expanded by the development of microfluidics technology. Furthermore, cell dissociation and tissue digestion have been adapted for a large range of microfluidic devices, which have increased the adoption of SEA technology and further boosted industry growth.

The rising investment flow in R&D in this space is reflected in the rising number of research publications. For instance, in April 2020, A USD 2 million funding round was headed by the venture capital firm i&i Biotech Fund for Sampling Human, a young life science technology startup that has created a diagnostic platform that uses genetically modified cells to examine other cells in their environment (i&i Bio). Further, R&D and business growth will all be advanced by the investment. Moreover, these expenditures indicate a better growth opportunity for this market because R&D efforts serve as the foundation for innovation. Additionally, scientists are analyzing geographic variability in gene expression profiles at the single-cell level, which is expected to increase the demand for consumables and equipment for analysis, thus propelling the industry’s growth.

Regional Insights

North America dominated the global market with a revenue share of over 35.90% in 2022. This can be attributed to factors such as multiple government funding programs, rising awareness regarding personal healthcare and related expenditure, faster adoption of novel analytical tools and techniques, and the availability of trained personnel. The U.S. is a major contributor to the industry growth in North America. For example, the U.S. NIH (National Institutes of Health) through its Common Fund Programs is supporting metabolomics research. Formerly, the NIH had also supported the single cell analysis program (SCAP) through the same funds. Extraordinary healthcare infrastructure, demand for personalized medicines, and the presence of key market players are some of the key factors fueling regional growth.

Asia Pacific is expected to exhibit the fastest CAGR over the forecast period. In the past years, the growing medical industry, rapidly developing healthcare systems, and increasing geriatric population have resulted in fueling the demand for cutting-edge diagnostic tools in the emerging economies of Asia Pacific. The focused efforts and outsourcing in this region have led to significant growth.

Some of the prominent players in the Single Cell Analysis Market include:

• Thermo Fisher Scientific, Inc.
• QIAGEN NV
• Bio-Rad Laboratories Inc.
• Illumina Inc.
• Merck KGaA
• Becton, Dickinson & Company
• Fluidigm Corporation
• 10x Genomics, Inc.
• BGI
• Novogene Corporation

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Single Cell Analysis market

• Product
  • Consumables
    • Reagents
    • Assay Kits
  • Instruments
    • Manual Instruments
    • Microscopes
    • Hemocytometers
    • Automated Instruments
    • Flow Cytometers
    • Next Generation Sequencing
    • PCR Systems
    • High-content Screening System
    • Cell Microarrays
    • Automated Cell Counters
• Application
  • Cancer
  • Immunology
  • Neurology
  • Stem Cell
  • Non-invasive Prenatal Diagnosis
  • In-vitro Fertilization
  • Others
• Workflow
  • Single Cell Isolation & Library Preparation
  • Downstream Analysis
  • Data Analysis
• End-user
  • Academic & Research Laboratories
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Diagnostic Laboratories
  • Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7579

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/